ADCC mediated by NK cells has been proposed as a fundamental mechanism of action of trastuzumab in HER2+ BC, based on several in vitro and in vivo studies (6, 7, 35, 62, 104, 105). The gene discussed is ERBB2; the disease is breast cancer.